City

Clinical trials near Shanghai, China

Active studies with a listed research site in Shanghai, China.

74active studies

40recruiting now

20countries represented

157largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 3

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

Dementia, Mild, Mild Cognitive ImpairmentCondition

Mazdutide, PlaceboTreatment

China8 locations

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSponsor

Updated 2026-09-02 · NCT07083154See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowPhase 1

A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

Type 2 Diabetes Mellitus Combined With Overweight or ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China12 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07747857See eligibility →

Recruiting nowPhase 3

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

OSA - Obstructive Sleep Apnea, ObesityCondition

XW003 injection, placebo with matching volumeTreatment

China1 locations

Hangzhou Sciwind Biosciences Co., Ltd.Sponsor

Updated 2026-08-28 · NCT07434050See eligibility →

Recruiting nowPhase 3

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Obesity, OverweightCondition

Elecoglipron, PlaceboTreatment

China, Hong Kong49 locations

AstraZenecaSponsor

Updated 2026-08-27 · NCT07775404See eligibility →

Recruiting nowNot applicable

Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')

Weight LossCondition

Treatment groupTreatment

China1 locations

Boston Scientific CorporationSponsor

Updated 2026-08-27 · NCT07195708See eligibility →

Recruiting nowPhase 3

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Obesity, OverweightCondition

Enicepatide, PlaceboTreatment

China18 locations

Hoffmann-La RocheSponsor

Updated 2026-08-13 · NCT07670416See eligibility →

Recruiting nowNot applicable

Fecal Microbiota Transplantation for Obese Women With Polyendocrine Metabolic Ovarian Syndrome

PCOS (Polycystic Ovary Syndrome)Condition

oral Fecal Microbiota Transplantation, PlaceboTreatment

China1 locations

Shanghai Changzheng HospitalSponsor

Updated 2026-08-12 · NCT07746635See eligibility →

Recruiting nowNot applicable

Cognitive Effects of Hesperidin in Overweight/Obese Older Adults

Cognitive Dysfunction, Overweight and ObesityCondition

HesperidinTreatment

China1 locations

Min HouSponsor

Updated 2026-08-06 · NCT07750223See eligibility →

Recruiting nowNot applicable

The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics

Prader-Willi SyndromeCondition

probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG, Prebiotics with galactomannan and oligofructoseTreatment

China1 locations

Children's Hospital of Fudan UniversitySponsor

Updated 2026-07-06 · NCT05791604See eligibility →

Recruiting nowNot applicable

Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia

Obesity & Overweight, HyperlipidemiaCondition

Spermidine, PlaceboTreatment

China1 locations

Shanghai 10th People's HospitalSponsor

Updated 2026-06-23 · NCT07662330See eligibility →

Recruiting nowPhase 2, Phase 3

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Atypical Endometrial Hyperplasia, Fertility IssuesCondition

Intensive Lifestyle Intervention (ILI), Megestrol Acetate 160 MG Oral TabletTreatment

China1 locations

Xiaojun ChenSponsor

Updated 2026-06-04 · NCT05316493See eligibility →

Recruiting nowPhase 2

Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS

PCOS (Polycystic Ovary Syndrome)Condition

GLP-1/FGF21 dual agonist (HEC88473)Treatment

China1 locations

Shanghai Zhongshan HospitalSponsor

Updated 2026-05-29 · NCT07616037See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Overweight, ObesityCondition

IBI362, PlaceboTreatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2026-05-27 · NCT07469800See eligibility →

Recruiting nowNot applicable

Genetics of Obesity in Chinese Youngs

Obesity, Metabolic SyndromeCondition

Intervention not listedTreatment

China1 locations

Shanghai Jiao Tong University School of MedicineSponsor

Updated 2026-05-12 · NCT01084967See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes

ObesityCondition

HDM1005 dose level 1, HDM1005 dose level 2Treatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2026-04-13 · NCT07521631See eligibility →

Recruiting nowNot applicable

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

Obesity, Weight ControlCondition

Mazdutide, Intensive Lifestyle InterventionTreatment

China13 locations

Shanghai Zhongshan HospitalSponsor

Updated 2026-04-08 · NCT07517042See eligibility →

Recruiting nowPhase 1

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

Part A: Healthy Part B: Overweight or ObesityCondition

Placebo, IBI3032 tabletsTreatment

China1 locations

Innovent Biologics Technology Limited (Shanghai R&D Center)Sponsor

Updated 2026-04-08 · NCT07160400See eligibility →

Recruiting nowPhase 1

A Food-Effect Study of CX11 in Healthy Participants

Obesity & Overweight, Type 2 DiabetesCondition

CX11 (VCT220)Treatment

China1 locations

Vincentage Pharma Co., LtdSponsor

Updated 2026-03-27 · NCT07349381See eligibility →

Recruiting nowNot applicable

Effects of Auricular Acupressure Versus Intermittent Dietary Restriction in Children With Gastric Heat and Dampness Obstruction

Obesity, ChildhoodCondition

Auricular acupressure of traditional Chinese Medicine, Intermittent low carbohydrate dietTreatment

China1 locations

Children's Hospital of Fudan UniversitySponsor

Updated 2026-03-19 · NCT05847478See eligibility →

Recruiting nowPhase 1, Phase 2

The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment

Mild Cognitive Impairment, Overweight or ObesityCondition

MetfominTreatment

China1 locations

Fudan UniversitySponsor

Updated 2026-02-09 · NCT07395960See eligibility →

Recruiting nowPhase 1

Evaluate LAE102 in Healthy and Overweight/Obese Subjects

Overweight and Obese VolunteersCondition

LAE102 intravenous administration, placebo intravenous administrationTreatment

China1 locations

Laekna LimitedSponsor

Updated 2026-01-09 · NCT06493084See eligibility →

Recruiting nowNot applicable

Asiaticoside for Treating Overweight/Obesity

Overweight , ObesityCondition

Asiaticoside tabletsTreatment

China1 locations

Shanghai Zhongshan HospitalSponsor

Updated 2025-12-24 · NCT07241533See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes

Obesity & OverweightCondition

HDM1005 1, HDM1005 2Treatment

China1 locations

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Sponsor

Updated 2025-12-12 · NCT07279194See eligibility →

Recruiting nowNot applicable

High Flow Nasal Cannula and Mask Oxygenation in Patients With Visceral Obesity Undergoing Sedated Gastroscopy

High Flow Nasal Cannula, Body Roundness IndexCondition

High Flow Nasal Cannula Oxygenation, Face Mask OxygenationTreatment

China1 locations

Shanghai Zhongshan HospitalSponsor

Updated 2025-12-01 · NCT07159022See eligibility →

Recruiting nowNot applicable

Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens

Metabolic Syndrome, DiabetesCondition

Intervention not listedTreatment

China1 locations

Shanghai Changzheng HospitalSponsor

Updated 2025-09-08 · NCT07043166See eligibility →

Recruiting nowNot applicable

China Health Big Data

Osteoporosis, ObesityCondition

Intervention not listedTreatment

China6 locations

Beijing Jishuitan HospitalSponsor

Updated 2025-08-17 · NCT03699228See eligibility →

Recruiting nowPhase 2, Phase 3

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Endometrial Neoplasms, Atypical Endometrial HyperplasiaCondition

GnRHa, Letrozole 2.5mgTreatment

China2 locations

Xiaojun ChenSponsor

Updated 2025-08-11 · NCT05316935See eligibility →

Recruiting nowPhase 2, Phase 3

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Endometrial Neoplasms, Atypical Endometrial HyperplasiaCondition

GnRH antagonist, Letrozole 2.5mgTreatment

China2 locations

Xiaojun ChenSponsor

Updated 2025-08-11 · NCT06379113See eligibility →

Recruiting nowNot applicable

Effect of Low Valine Diet on Body Weight and Metabolic Parameters

Overweight/obesity, Metabolic Associated Fatty Liver DiseaseCondition

Short-term continuous normal meal replacement, Short-term continuous low-valine meal replacementsTreatment

China1 locations

Shanghai Zhongshan HospitalSponsor

Updated 2025-03-19 · NCT06883578See eligibility →

Recruiting nowPhase 1, Phase 2

Efficacy of Mazdutide for Treating PCOS

Polycystic Ovary SyndromeCondition

MazdutideTreatment

China1 locations

Shanghai Zhongshan HospitalSponsor

Updated 2024-10-24 · NCT06519656See eligibility →

Recruiting nowNot applicable

The Effects of Remimazolam on the Incidence of Severe Hypoxia During Sedated Hysteroscopy for Assisted Reproduction in Overweight or Obese Patients

Hypoxia, HysteroscopyCondition

remimazolam, PropofolTreatment

China1 locations

RenJi HospitalSponsor

Updated 2024-09-19 · NCT06187896See eligibility →

Recruiting nowNot applicable

Obesity Queue Database

ObesityCondition

otherTreatment

China1 locations

RenJi HospitalSponsor

Updated 2024-04-30 · NCT06391320See eligibility →

Recruiting nowNot applicable

Effect of Electroacupuncture on Obesity

ObesityCondition

Electroacupuncture, Sham acupunctureTreatment

China1 locations

Shanghai Municipal Hospital of Traditional Chinese MedicineSponsor

Updated 2022-11-10 · NCT05237089See eligibility →

Recruiting nowNot applicable

Effects of Lifestyle Intervention on Childhood Outcomes in LGA Infants

Childhood OverweightCondition

Comprehensive lifestyle interventionTreatment

China1 locations

Xinhua Hospital, Shanghai Jiao Tong University School of MedicineSponsor

Updated 2021-02-05 · NCT04661449See eligibility →

Recruiting nowNot applicable

Overweight and Obesity and Puberty Development Cohort Study

Precocious Puberty, Overweight and ObesityCondition

Anthropometric measuring, Growth environment evaluationTreatment

China1 locations

Shanghai Jiao Tong University School of MedicineSponsor

Updated 2020-02-05 · NCT04113070See eligibility →

Opening soonPhase 3

A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

Obesity, OverweightCondition

Berobenatide, PlaceboTreatment

China33 locations

PfizerSponsor

Updated 2026-09-04 · NCT07792954See eligibility →

Opening soonPhase 1

A Clinical Trial of TQF3250 Capsules in Overweight/Obese Trial Participants With Poor Weight Control Through Simple Lifestyle Intervention

Overweight/ObesityCondition

TQF3250 capsules, TQF3250 placeboTreatment

China10 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2026-09-01 · NCT07798284See eligibility →

Opening soonPhase 1

A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.

Obesity / OverweightCondition

TQF6422 Injection, TQF6422 PlaceboTreatment

China1 locations

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Sponsor

Updated 2026-08-31 · NCT07794111See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

China13 locations

Eli Lilly and CompanySponsor

Updated 2026-08-27 · NCT07790861See eligibility →

Opening soonPhase 2

Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer

Obesity, OverweightCondition

Mazdutide(Dual GLP-1R/GCGR Agonist), PlaceboTreatment

China6 locations

Tongji HospitalSponsor

Updated 2026-08-24 · NCT07781150See eligibility →

Opening soonPhase 4

QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

Type 2 Diabetic Kidney DiseaseCondition

empagliflozin, FinerenoneTreatment

China1 locations

Huijie ZhangSponsor

Updated 2026-08-20 · NCT07775846See eligibility →

Opening soonNot applicable

Efficacy of Different Dietary Pattern in Long-term Weight Management

Obesity and Overweight, Dietary InterventionCondition

Individualized dietary intervention, Traditional energy-restricted balanced dietTreatment

China1 locations

Guang NingSponsor

Updated 2026-08-19 · NCT07773558See eligibility →

Opening soonPhase 1

Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants

Healthy Participants, Overweight or Obese ParticipantsCondition

SAD: subcutaneous injection in the abdomen, MAD: subcutaneous injection in the abdomenTreatment

China1 locations

Innovent Biologics (Suzhou) Co. Ltd.Sponsor

Updated 2026-08-14 · NCT07765160See eligibility →

Opening soonNot applicable

Effects of Exercise Sequence and Meal Sequence on Weight Management Among Children and Adolescents With Overweight or Obesity: The STEP Trial

Obesity & Overweight, Insulin ResistanceCondition

Carbohydrate-last eating, Sequential trainingTreatment

China9 locations

Peking UniversitySponsor

Updated 2026-07-17 · NCT07712068See eligibility →

Opening soonPhase 3

A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis

Participants With Obesity and Knee OsteoarthritisCondition

Ribupatide Injection, PlaceboTreatment

China1 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-07-17 · NCT07709910See eligibility →

Opening soonPhase 2

A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity

Overweight or ObesityCondition

HRS-4729 Injection, HRS-4729 InjectionTreatment

China1 locations

Fujian Shengdi Pharmaceutical Co., Ltd.Sponsor

Updated 2026-07-08 · NCT07690826See eligibility →

Opening soonNot applicable

Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention

Gastric RetentionCondition

No Intervention: Observational CohortTreatment

China1 locations

Fudan UniversitySponsor

Updated 2025-12-11 · NCT07276763See eligibility →

Opening soonNot applicable

Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention

Gastric RetentionCondition

EsophagogastroduodenoscopyTreatment

China1 locations

Fudan UniversitySponsor

Updated 2025-09-05 · NCT07156591See eligibility →

Opening soonNot applicable

Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores

Gastric RetentionCondition

EsophagogastroduodenoscopyTreatment

China1 locations

Fudan UniversitySponsor

Updated 2025-09-03 · NCT07152756See eligibility →

Opening soonNot applicable

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

Severe ObesityCondition

Sleeve gastrectomy plus early mazdutide initiation, Sleeve gastrectomy followed with early mazdutide placebo initationTreatment

China14 locations

Beijing Friendship HospitalSponsor

Updated 2025-08-21 · NCT07135141See eligibility →

Opening soonPhase 3

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

Acute Ischemic StrokeCondition

Semaglutide 0.5 mg, Normal SalineTreatment

China1 locations

RenJi HospitalSponsor

Updated 2025-06-22 · NCT07030621See eligibility →

Opening soonPhase 2

The Efficacy and Safety of Puerarin in Obesity Treatment

Metabolic Diseases, Obesity/TherapyCondition

Puerarin, PlaceboTreatment

China1 locations

Ruijin HospitalSponsor

Updated 2025-05-21 · NCT06968208See eligibility →

Opening soonPhase 4

PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults

Non-diabetic ObesityCondition

PEG-rhGH Injection + Semaglutide Injection, Semaglutide InjectionTreatment

China1 locations

Shanghai Zhongshan HospitalSponsor

Updated 2025-03-07 · NCT06863363See eligibility →

Opening soonPhase 3

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

ObesityCondition

TQF3510 (Semaglutide Injection), Wegovy®Treatment

China66 locations

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Sponsor

Updated 2024-12-18 · NCT06738979See eligibility →

Opening soonNot applicable

Study of Acupuncture to Control Weight and Improve Pregnancy Rates in Overweight/Obese PCOS Patients

Polycystic Ovary Syndrome, MetforminCondition

Acupuncture+lifestyle intervention, Metformin+lifestyle interventionTreatment

China1 locations

RenJi HospitalSponsor

Updated 2024-12-04 · NCT06717087See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Shanghai, China

Current studies

Related cities